Psychosocial burden and quality of life impairment in adults with vitiligo: a cross-sectional assessment Authors: Asma Malawi Alshahrani, Rajalakshimi Vasudevan, Amjad Hmlan, Abdullah Mohammed Asiri, Ahmad Mohammed Assiri, Praveen Devanandan, Geetha Kandasamy, Krishnaraju Venkatesan Published: 2026 ABSTRACT BackgroundVitiligo, a chronic autoimmune depigmenting disorder, substantially affects patients’ psychosocial well-being despite its benign physical course. Limited evidence from Saudi Arabia explores the quality-of-life (QoL) impact of vitiligo and its clinical correlates.ObjectiveTo assess QoL impairment among adults with vitiligo and to determine the relationship between disease characteristics and Dermatology Life Quality Index (DLQI) scores.MethodsA cross-sectional, questionnaire-based study was conducted among 121 adults attending a tertiary dermatology center in Saudi Arabia. Data on sociodemographic and clinical variables were collected, and QoL was evaluated using the validated DLQI instrument (Arabic/English). Statistical analyses included descriptive measures, χ2 tests, Pearson’s correlation, and one-way ANOVA, with p ≤ 0.05 considered significant.ResultsHigher DLQI scores were significantly associated with greater body-surface-area involvement, facial + body distribution, and bilateral lesions. Emotional distress, clothing limitations, and restricted social and leisure activities were the most affected domains.ConclusionVitiligo markedly impairs QoL, particularly when lesions are visible and extensive. Incorporating routine DLQI screening and psychosocial support into dermatologic practice may improve holistic patient management. Introduction Vitiligo is a chronic, idiopathic skin disorder characterized by the selective destruction of melanocytes, leading to depigmented white patches on the skin and mucous membranes. It is an acquired condition with a worldwide prevalence ranging from 0.5% to 2%, although some reports cite figures as high as 4% depending on geographic and ethnic variability (Krüger & Schallreuter, 2013). The condition can begin at any age, but the majority of cases (approximately 95%) present before the age of 40, with an average onset around the second decade of life (Handa & Dogra, 2003). Despite not causing physical pain or direct systemic complications, vitiligo can result in profound psychological distress and social stigma. This is particularly the case in cultures where even mild skin deformities are socially sensitive or misunderstood. In certain regions, vitiligo is still erroneously associated with leprosy, contributing to isolation, anxiety, and avoidance behaviors in affected individuals (Parsad, Dogra & Kanwar, 2003). Additionally, vitiligo often coexists with autoimmune disorders such as thyroid dysfunction, type 1 diabetes mellitus, Addison’s disease, rheumatoid arthritis, and alopecia areata, further complicating disease management and impacting quality of life (Silverberg & Silverberg, 2013). Clinically, vitiligo is classified into segmental and non-segmental types, with non-segmental vitiligo being the most common form. Its presentation can vary widely among patients in terms of lesion location, symmetry, and rate of progression (Patel, Kubba & Kubba, 2013). Various treatment modalities are available, including topical corticosteroids, calcineurin inhibitors, phototherapy (e.g., narrowband UVB), depigmenting agents, and skin grafting techniques (Narayan et al., 2021). However, these treatments often provide inconsistent results, require long durations, and are not curative, making disease control and cosmetic satisfaction difficult to achieve. Beyond the dermatological manifestations, vitiligo exerts a considerable psychosocial burden. Numerous studies have indicated that patients with vitiligo experience significantly lower self-esteem and higher levels of psychological distress compared to healthy individuals. Psychiatric comorbidities, such as depression, anxiety disorders, and social phobias, have been reported in up to 25% of patients with vitiligo (Mattoo et al., 2001, 2002). Women and younger patients, in particular, report greater psychological impact, likely due to sociocultural pressures and aesthetic concerns (Hedayat et al., 2016). Affected individuals may avoid social events, develop fear of judgment or rejection, and report impaired personal relationships and sexual health. The term “quality of life” (QoL) encompasses a broad range of physical, psychological, emotional, and social dimensions of health and well-being. In dermatological practice, evaluating QoL has become increasingly important, especially for chronic skin conditions that have visible manifestations but may not necessarily correlate with the severity of physical symptoms. Tools such as the Dermatology Life Quality Index (DLQI), introduced by Finlay & Khan (1994), have become essential for assessing patient-reported outcomes and gauging treatment effectiveness. The DLQI includes 10 questions focused on symptoms, personal relationships, leisure, work/study, daily activities, and treatment side effects. It is a validated, easy-to-administer instrument that allows clinicians to quantify the psychosocial burden of skin conditions, including vitiligo (Basra et al., 2008). Previous studies have demonstrated that the impact of vitiligo on QoL is not solely determined by disease extent. Factors such as lesion location (e.g., involvement of the face or hands), visibility, stability of disease, treatment history, and even the cultural context can significantly influence patient perceptions and experiences (Silverberg & Silverberg, 2013; Wang, Wang & Zhang, 2011). Yet, despite its high prevalence in Middle Eastern and South Asian populations, limited data exist from Saudi Arabia and neighbouring regions on how vitiligo affects QoL, and how demographic and clinical variables interact in this regard. Rai & Harikumar (2017) found that vitiligo patients, particularly younger adults, exhibit higher depression scores and diminished QoL, underscoring the need for integrated care models. Similarly, Hedayat et al. (2016) demonstrated that vitiligo has a more significant impact on QoL in females and those with longer disease duration. Ghaderi & Saadatjoo (2014) highlighted that psychological support, including cognitive-behavioral therapy, could greatly enhance QoL in vitiligo patients, advocating a multidisciplinary treatment approach. Growing evidence suggests that impairment in social, leisure, and clothing-related domains among individuals with vitiligo may arise through stigma-mediated pathways, whereby visible skin lesions elicit negative social reactions that influence behavior. Empirical work has shown that prejudice toward people with vitiligo is measurable, varies with lesion visibility, and is associated with reduced willingness for social contact (Do Bú et al., 2024). This framework provides a theoretical basis for understanding why visibility-related domains are often prominent in vitiligo-related quality-of-life assessments. Given this background, it is evident that understanding the psychological and social dimensions of vitiligo is essential for holistic patient care. To our knowledge, this represents one of the larger Saudi cohorts evaluating quality-of-life outcomes in vitiligo using a validated dermatology-specific instrument. However, further research is needed to identify the specific factors most predictive of QoL impairment in diverse patient populations. This study aimed to quantify quality-of-life impairment among adult patients with vitiligo using the DLQI and to examine the association between overall DLQI score and key clinical characteristics, including body surface area (BSA) involvement, lesion visibility, and laterality. Secondary analyses explored the distribution of impairment across individual DLQI domains to descriptively characterize which aspects of daily life are most affected. Methodology Study design and setting This study employed a prospective cross-sectional design, defined as the prospective recruitment of participants over a fixed 6-month period, with all clinical and QoL assessments conducted at a single time point for each participant. The primary objective was to evaluate the psychosocial burden and quality of life among adults with vitiligo using a validated dermatology-specific instrument. The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, and the completed checklist is provided as File S2 (Von Elm et al., 2007; Raosoft Inc, 2024). Study population and sampling Clinically diagnosed adult patients (≥18 years) with vitiligo were prospectively recruited from outpatient dermatology clinics during a fixed 6-month study period. Eligibility was restricted to adults in accordance with ethical approval, and no participants below 18 years of age were enrolled. A minimum sample size of 40 participants was estimated using the Raosoft Sample Size Calculator (95% confidence level, 5% margin of error), representing the minimum number required to achieve adequate precision. However, recruitment continued throughout the study period, resulting in a final analytic sample of 121 participants, thereby improving statistical power and robustness of the analyses. Diagnostic confirmation Vitiligo diagnosis was confirmed clinically by a dermatologist; cases with alternative depigmenting diagnoses were not classified as vitiligo and were therefore not enrolled. Inclusion criteria Adults aged 18 years and above diagnosed with vitiligo by a dermatologist.Both male and female participants.Patients who provided informed consent and were willing to complete the questionnaire. Adults aged 18 years and above diagnosed with vitiligo by a dermatologist. Adults aged 18 years and above diagnosed with vitiligo by a dermatologist. Both male and female participants. Both male and female participants. Patients who provided informed consent and were willing to complete the questionnaire. Patients who provided informed consent and were willing to complete the questionnaire. Exclusion criteria Patients with known psychiatric disorders requiring active treatment (as identified by self-report and/or medical record documentation).Non-consenting or uncooperative individuals. Patients with known psychiatric disorders requiring active treatment (as identified by self-report and/or medical record documentation). Patients with known psychiatric disorders requiring active treatment (as identified by self-report and/or medical record documentation). Non-consenting or uncooperative individuals. Non-consenting or uncooperative individuals. Ethical approval and consent Ethical approval for this study was obtained from the Research Ethics Committee, College of Pharmacy, King Khalid University (Approval No. ECM#2021-5503). The study was conducted in accordance with the Declaration of Helsinki (World Medical Association, 2013). Written informed consent was obtained from all participants prior to data collection and a blank form has been submitted as Supplemental File. Participants were informed about the purpose of the study, procedures, potential risks and benefits, and their right to withdraw at any time without penalty. Confidentiality and anonymity were strictly maintained. Study tool: questionnaire and DLQI instrument A structured, three-part questionnaire was used. It included: (1) sociodemographic data, (2) disease-specific characteristics, and (3) the Dermatology Life Quality Index (DLQI), a validated 10-item scale designed to assess the psychosocial impact of dermatologic conditions (Basra et al., 2008; Al Robaee, 2010). Each item was rated on a 4-point Likert scale from 0 (not at all) to 3 (very much), producing a total score range of 0–30. Higher scores indicated greater quality-of-life impairment. Use of DLQI instrument The DLQI was used to assess quality of life in vitiligo patients (Al Robaee, 2010; Bibeau et al., 2023). Use of the Dermatology Life Quality Index (DLQI): The DLQI, developed by Finlay & Khan (1994), was used to assess quality of life in patients with vitiligo. The authors obtained a free licence (ID CUQoL4062) from Cardiff University, UK, granting permission to use and reproduce the DLQI questionnaire in this study and for open-access publication under the CC BY 4.0 licence. The DLQI was employed in its validated English and Arabic versions with full acknowledgment of copyright ownership (© 1994, Cardiff University, UK). The permission request and correspondence evidence have been provided as Supplemental File. The Arabic version of the DLQI, used alongside the English version, was pilot tested among five patients to ensure clarity and cultural appropriateness. The internal consistency in this cohort was satisfactory (Cronbach’s alpha = 0.82), in accordance with standard reliability benchmarks (Tavakol & Dennick, 2022). Data collection procedure Trained healthcare researchers facilitated questionnaire completion, ensuring confidentiality and anonymity. No personal identifiers were recorded. Responses were double-entered into Microsoft Excel to prevent data entry errors, and verified files were exported to IBM SPSS Statistics for Windows, Version 21.0 for statistical analysis (IBM Corporation, 2023). Assessment of psychiatric comorbidity Psychiatric comorbidity was not screened using a formal psychiatric scale. Instead, exclusion was limited to participants with previously diagnosed psychiatric disorders requiring active treatment, identified through patient self-report and/or documentation in the medical record. This approach was applied to reduce potential confounding of DLQI scores by severe pre-existing psychiatric illness. Clinical assessment of vitiligo Clinical characteristics of vitiligo were documented by the treating dermatologist at the time of patient evaluation. Body surface area (BSA) involvement was estimated using routine clinical assessment, based on visual approximation and the patient’s palm method (approximately 1% of total BSA). Lesion distribution was recorded by anatomical involvement and, for analysis, categorized as single-region involvement (face/neck only OR body only [trunk/extremities]) vs. combined face + body involvement. Laterality was recorded as unilateral or bilateral based on clinical examination. Classification of vitiligo as localized or generalized followed standard dermatology clinic documentation, where localized vitiligo referred to regionally confined non-segmental disease and generalized vitiligo to more widespread, multi-regional involvement. In this clinic documentation, ‘localized’ refers to regionally confined non-segmental disease and may still be bilateral; therefore, laterality and BSA were analyzed separately. Pilot study and validation A pilot study was conducted with five adult vitiligo patients to assess the clarity, language comprehensibility, and relevance of questionnaire items. Feedback led to minor modifications in phrasing for local contextual appropriateness. Internal consistency of the DLQI in this population was confirmed with Cronbach’s alpha >0.80, in line with earlier studies (Fekete, Iantovics & Fekete, 2024). Statistical analysis Descriptive statistics (frequency, percentage, mean ± SD) were used to summarize demographic, clinical, and DLQI domain responses. Primary inferential analyses examined associations between total DLQI score and key clinical variables (BSA involvement, lesion distribution, laterality, disease duration, and gender) using chi-square tests, one-way ANOVA, or Pearson correlation as appropriate. Analyses of individual DLQI item responses were conducted descriptively to illustrate patterns of quality-of-life impairment across domains and were not intended to test specific causal hypotheses. Analyses were primarily bivariate, consistent with the exploratory objective of identifying clinical correlates of DLQI in this clinic-based cohort. Multivariable modeling was not prioritized because key predictors (e.g., BSA, visibility, and laterality) may be interrelated; larger samples will allow more stable multivariable estimates. Statistical significance was set at p ≤ 0.05 (IBM Corporation, 2023; Field, 2024). Results Socio-demographic characteristics A total of 121 patients with clinically diagnosed vitiligo were enrolled. Of these, 55 (45.5%) were male and 66 (54.5%) were female, yielding a near-equal gender distribution. The majority were aged 30–39 years (49.6%), followed by 20–29 years (35.5%), and 18–19 years (14.9%). Most participants had achieved university-level education (60.3%), while 32.2% had school-level education and 7.4% were illiterate. Regarding marital status, 52.1% were married and 47.9% were single. Occupationally, 70.2% of respondents were students, unemployed, or self-employed in business; 19.8% were government employees, and 9.9% worked in the private sector. A majority resided in regional cities (55.4%), followed by zonal towns (32.2%), district towns (9.9%), and rural areas (2.5%). Most respondents lived in large families (≥5 members; 75.2%), whereas 19.8% had 3–4 members and 5.0% lived in smaller families of 1–2 members (Table 1). The study cohort primarily comprised urban, educated adults in the 20–39-year age group, with balanced gender representation and predominantly large family households. 10.7717/peerj.21660/table-1Table 1Socio demographic details.Socio-demographic characteristics N %GenderMale5545.45Female6654.55Age18–19 years1814.8720–29 years4335.5330–39 years6049.58EducationIlliterate97.43School3932.23University education7360.33Marital statusSingle5847.93Married6352.07OccupationGovernment employees2419.83Private employees129.91Others (students, unemployed, business)8570.24ResidenceRegional cities6755.37Zonal towns3932.23District towns129.91Rural settings32.47Family size1–264.953–42419.83≥59175.21 Socio demographic details. Clinical profile of vitiligo patients As shown in Table 2, 33.1% of participants had disease duration <5 years, 27.3% had 5–10 years, 12.4% had 10–15 years, and 27.3% had 15–20 years. Regionally confined (localized) vitiligo was most common (70.3%), while 29.8% presented with generalized disease. Regarding disease stability, 34.7% reported a slowly progressive course, 27.3% were stable, 19.8% rapidly progressive, and 18.2% improving. Treatment response varied: 32.2% had never received treatment, 28.1% reported moderate improvement, 22.3% poor, and 19.8% good response. Only 4.9% had other visible skin disorders. Body-surface-area (BSA) involvement was <25% in 42.1%, 26–50% in 28.1%, 51–75% in 9.9%, and 76–100% in 19.8%. Lesions were distributed over both face and body in 72.7%, and limited to to a single region (face/neck only or body only) in 27.3%. Bilateral involvement predominated (85.1%), with unilateral presentation in 14.9% of cases. 10.7717/peerj.21660/table-2Table 2Clinical characteristics.ParameterCategoryN (%)Disease durationLess than 5 years40 (33.1)5–<10 years33 (27.3)10–<15 years15 (12.4)15–<20 years33 (27.3)Type of diseaseGeneralized36 (29.8)Localized85 (70.2)Disease stabilityImproving22 (18.2)Stable33 (27.3)Slowly progressive42 (34.7)Rapidly progressive24 (19.8)Treatment responsePoor27 (22.3)Moderate34 (28.1)Appropriate24 (19.8)No treatment39 (32.2)Other visible skin disorderYes6 (5)No115 (95.0)Body surface area (BSA) affected1–2551 (42.1)26–5034 (28.1)51–7512 (9.9)76–10024 (19.8)DistributionFace only/body only33 (27.3)Face + body88 (72.7)LateralityUnilateral18 (14.9)Bilateral103 (85.1) Note: Body refers to trunk and/or extremities. Single-region involvement includes face/neck only or body only. Localized vitiligo was not restricted to unilateral disease and may include multifocal lesions confined to limited anatomical regions. Clinical characteristics. Note: Body refers to trunk and/or extremities. Single-region involvement includes face/neck only or body only. Localized vitiligo was not restricted to unilateral disease and may include multifocal lesions confined to limited anatomical regions. Quality-of-life (QoL) assessment using DLQI Analysis of DLQI responses demonstrated that the majority of participants experienced moderate-to-severe quality-of-life impairment. Item-level responses were examined to descriptively characterize the domains most affected, rather than to test domain-specific hypotheses. Table 3 summarizes the distribution of responses across DLQI domains, highlighting areas of greatest patient-reported burden. 10.7717/peerj.21660/table-3Table 3Distribution of responses across DLQI domains.DLQI domainVery much N (%)A lot N (%)A little N (%)Not at all N (%)Itching/burning19 (15.7)24 (19.8)24 (19.8)54 (44.6)Self-conscious about lesion24 (19.8)15 (12.4)19 (15.7)63 (52.1)Ability to shop/care for home24 (19.8)36 (29.8)16 (13.2)45 (37.2)Influence on clothing30 (24.8)24 (19.8)15 (12.4)52 (43.0)Social/leisure activities30 (24.8)27 (22.3)18 (14.9)46 (38.0)Sports participation30 (24.8)30 (24.8)15 (12.4)46 (38.0)Work/study interference24 (19.8)12 (9.9)21 (17.4)64 (52.9)Relationship with family/friends27 (22.3)15 (12.4)19 (15.7)60 (49.6)Sexual function3 (2.5)21 (17.4)19 (15.7)78 (64.5)Effect of treatment on QoL33 (27.3)9 (7.4)42 (34.7)37 (30.6) Distribution of responses across DLQI domains. Participants frequently reported considerable interference in multiple daily activities. Approximately 35.5% experienced pronounced itching or burning sensations, while 32.2% indicated feeling very self-conscious about their condition. Clothing preferences were substantially influenced in 44.6% of respondents, reflecting heightened self-image concerns associated with visible lesions. Social and leisure participation was negatively affected in nearly half of the patients (47.1%), and 49.6% reported restrictions in sports or outdoor activities. Moreover, 27.3% of participants experienced interference with their work or study performance, while 34.7% noted strain in interpersonal relationships. Although the domain of sexual activity was less frequently reported, 19.8% still described a measurable impact. Finally, 34.7% acknowledged that ongoing or previous treatment efforts influenced their perceived quality of life. Overall, these findings indicate that vitiligo exerts a significant psychosocial burden, particularly through its visible manifestations and resulting social and emotional limitations. The DLQI analysis underscores the importance of integrating psychological support and counselling into routine vitiligo management. Primary inferential analyses focused on associations between total DLQI score and clinical characteristics, as summarized in Table 4. BSA involvement showed a significant positive correlation with DLQI scores (r = 0.47, p = 0.004) as illustrated in the Fig. 1. Bilateral lesions were linked to higher mean DLQI (12.2 ± 3.8) compared with unilateral (7.4 ± 2.9). Facial + body involvement corresponded with higher DLQI (13.1 ± 4.1) than face-only/body-only (8.5 ± 3.2). Gender difference (female > male) and disease duration showed non-significant trends toward higher DLQI. QoL impairment was primarily influenced by the extent, visibility, and distribution of lesions rather than duration or gender. 10.7717/peerj.21660/table-4Table 4Summary table.PredictorDirection of associationp-valueInterpretationBSA involvement↑ DLQI0.004Larger area → worse QoLBilateral vs. unilateral↑ DLQI0.02Bilateral → greater distressFacial + body lesions↑ DLQI<0.01Visibility → strong impactGender (female > male)Trend ↑0.07Not significantDisease durationTrend ↑0.09Not significant Summary table. Scatter plot. Correlation between BSA involvement and DLQI score. Exploratory analysis comparing mean DLQI across treatment response categories (poor, moderate, appropriate, no treatment) was conducted using one-way ANOVA (or Kruskal–Wallis if non-normal) in the Table 5. This analysis is presented in the Table 5. 10.7717/peerj.21660/table-5Table 5Exploratory analysis.Treatment response N Mean DLQI ± SDPoor response2712.63 ± 6.91Moderate response344.74 ± 7.10Appropriate response245.53 ± 5.31No treatment3910.90 ± 6.48 Note: Differences in DLQI scores across treatment-response groups were analyzed using one-way ANOVA (p = 0.66). As a robustness check due to non-normal distribution in some subgroups, a Kruskal–Wallis test was also performed (p = 0.59). Exploratory analysis. Note: Differences in DLQI scores across treatment-response groups were analyzed using one-way ANOVA (p = 0.66). As a robustness check due to non-normal distribution in some subgroups, a Kruskal–Wallis test was also performed (p = 0.59). Overall findings Out of 121 participants, 68.6% reported moderate-to-severe impairment (DLQI > 6). The mean total DLQI score (11.3 ± 4.2) corresponded to a large effect on daily living. Collectively, these results confirm that vitiligo imposes a substantial psychosocial burden, particularly among patients with visible and bilateral lesions. Discussion This study aimed to assess the quality of life (QoL) in adult patients with vitiligo using the Dermatology Life Quality Index (DLQI) and to evaluate the correlation between clinical characteristics of the disease and QoL impairment. The findings underscore the significant psychosocial impact of vitiligo, even in the absence of physical discomfort or systemic complications. In this cross-sectional cohort of 121 adults with vitiligo, QoL burden measured by DLQI was substantial: roughly two-thirds reported moderate-to-severe impairment, with the highest impact in social/leisure participation, clothing choices, sports, and self-consciousness domains. Clinically, greater BSA, facial + body involvement, and bilaterality were the strongest correlates of worse DLQI, while associations with gender and disease duration were weaker and did not reach statistical significance. Although ‘localized’ is sometimes interpreted as limited or unilateral, our classification reflects clinic documentation of regionally confined non-segmental disease, which can still be bilateral and may involve substantial cumulative BSA; hence BSA and laterality were evaluated as independent clinical correlates. These patterns reinforce that, for vitiligo, visibility and distribution often drive psychosocial burden more than crude extent or chronicity alone (Field, 2024; Rosmarin et al., 2024; Habib et al., 2024). Comparison with recent literature Our findings align with multi-country and national reports published over the last decade. The VALIANT program demonstrated that people with vitiligo worldwide experience broad psychosocial burden, especially when >5% BSA is affected, when facial/hands are involved, and in darker skin types; work and daily activities were frequently limited—mirroring our domain-level impairments in social/leisure and sports participation (Field, 2024). In a 2024 burden analysis, Rosmarin et al. (2024) similarly found worse HRQoL with more severe disease, facial location, and greater BSA, and noted that commonly used HRQoL tools can be insensitive to vitiligo-specific concerns—underscoring the need to pair DLQI with context-specific assessment or counseling. Within Saudi Arabia, Al-Shammari et al. (2021) (Central KSA) reported impaired DLQI among clinic attendees and highlighted social/psychological strain; our cohort’s magnitude and pattern of domain impacts are broadly concordant, though our larger sample and explicit correlation analyses extend those observations. A 2023 national analysis reported low-to-moderate median DLQI but noted important associations with lesion characteristics and psychological symptoms, consistent with our finding that visibility rather than duration is the dominant driver of distress (Mohammed et al., 2023). A focused synthesis from the Kingdom further estimated depression prevalence ≈46% among vitiligo patients and DLQI means ~6–15, confirming the public mental-health relevance of dermatologic QoL screening (Alzeer et al., 2023). Psychosocial impairment in vitiligo is likely mediated by social visibility and stigma-related responses, which can lead to avoidance behaviors (e.g., clothing concealment, reduced leisure participation). Our clinic-based estimates should be interpreted with the recognition that exclusion of patients with severe psychiatric illness may yield conservative QoL burden estimates. Recent European position and review articles likewise emphasize stigma and self-image as key pathways by which vitiligo reduces QoL—precisely the themes reflected in our “self-consciousness” and “influence on clothing” domains (Fekete, Iantovics & Fekete, 2024; Böhm et al., 2024; Vyas et al., 2025). Interpretation Three practical implications emerge. First, anatomical visibility (face + body) and bilaterality appear to index social salience; patients with these distributions reported significantly higher DLQI. This supports proactive psychosocial screening in clinics whenever lesions are high-visibility or bilateral, even when total BSA seems modest (Fekete, Iantovics & Fekete, 2024; Rosmarin et al., 2024; Habib et al., 2024). Second, domain-level signals (social/leisure, clothing, sports) point to behavioral avoidance and body-image concerns, suggesting benefit from brief cognitive-behavioral strategies, peer support, and culturally sensitive education integrated into dermatology services (Fekete, Iantovics & Fekete, 2024; Rosmarin et al., 2024; Böhm et al., 2024). Third, while DLQI captured meaningful burden, recent work cautions that generic dermatology indices may under-represent vitiligo-specific experiences; targeted counseling and, where feasible, adjunct patient-reported instruments (or DLQI item-level review) may provide a more responsive picture of change with therapy (Fekete, Iantovics & Fekete, 2024; Habib et al., 2024; Böhm et al., 2024; Vyas et al., 2025). Strengths and limitations Strengths include (i) a consecutive clinic sample of 121 adults; (ii) standardized DLQI administration in Arabic/English; (iii) analysis of distributional patterns (facial + body; laterality) rather than BSA alone; and (iv) adherence to STROBE with open raw data. Limitations should be acknowledged. The cross-sectional design precludes causal inference, and unmeasured confounders (e.g., skin phototype, coping style, or comorbid autoimmune conditions such as thyroid disease) may have influenced quality-of-life outcomes. Although convenience sampling is common in dermatology clinics, it may limit generalizability beyond tertiary care settings. In addition, participants with pre-existing psychiatric disorders requiring active treatment were excluded, which may have led to an underestimation of psychosocial burden in routine clinical practice. Furthermore, analyses were primarily bivariate, and residual confounding cannot be excluded; future studies with larger samples should apply multivariable models to determine whether lesion visibility, laterality, and body surface area remain independently associated with DLQI. Finally, although the DLQI is a validated and widely used dermatology-specific instrument, it was not designed exclusively for vitiligo; qualitative approaches and vitiligo-specific instruments may better capture nuances related to stigma, social perception, and color contrast (Field, 2024; Rosmarin et al., 2024; Böhm et al., 2024). Clinical and public-health implications Routine DLQI screening can triage patients to counseling early, especially those with visible and bilateral patterns. Recognizing stigma and social prejudice as modifiable drivers of quality-of-life impairment underscores the importance of psychosocial counseling, patient education, and community-level stigma reduction, alongside dermatologic treatment. Education addressing misconceptions and stigma in families and communities (school/workplace policies, public campaigns) is likely to reduce avoidance and improve adherence. Given signals that sports and outdoor activities are constrained, clinicians might consider UV-protective strategies, cosmetic camouflage, or graded exposure to rebuild confidence—approaches that patients in qualitative programs report as enabling (IBM Corporation, 2023; Field, 2024). Future research Longitudinal work linking treatment response to domain-level DLQI change would clarify which interventions most improve social participation and body image. Mixed-methods designs (DLQI + interviews) could illuminate mechanisms of stigma and better guide culturally tailored psychosocial care. Finally, studies stratified by skin phototype and lesion site will refine predictive models of QoL and help allocate supportive resources more efficiently (Field, 2024; Rosmarin et al., 2024; Vyas et al., 2025). Conclusion This study confirms that vitiligo significantly impairs the quality of life of adult patients, especially those with extensive, bilateral, and facial involvement. The emotional and social domains of life are most affected, underlining the need for a holistic, patient-centered approach to care. Dermatologists should not only aim for skin repigmentation but also incorporate psychological support and counseling into routine care. Increasing public awareness and reducing stigma through community education may further improve outcomes for individuals living with vitiligo. Recommendations Routine QoL screening using DLQI in dermatology clinics.Integration of mental health services in vitiligo care.Public awareness campaigns to reduce stigma.Further longitudinal studies to assess treatment impact on QoL. Routine QoL screening using DLQI in dermatology clinics. Routine QoL screening using DLQI in dermatology clinics. Integration of mental health services in vitiligo care. Integration of mental health services in vitiligo care. Public awareness campaigns to reduce stigma. Public awareness campaigns to reduce stigma. Further longitudinal studies to assess treatment impact on QoL. Further longitudinal studies to assess treatment impact on QoL. Supplemental Information STROBE Checklist. Raw data. Blank informed consent. Informed consent.